The veterinary API market left the bottom for a continuous rebound

The veterinary API market left the bottom for a continuous rebound. According to the China Veterinary Drugs and Feed Trade Center monitoring data, the veterinary API price index (VPi) has gone up for five consecutive weeks. Its movement reflects that the veterinary market is still in the bottoming out phase, with the overall market liquidity and trading activity on the rise.

However, the market performance of different products varies due to the varying demand for API varieties during the off-season of the domestic breeding industry.

Implementing the new version of the GMP standard on 1 June will inevitably remove some capacity from the production side, which will inevitably be reflected in the market price of APIs. 

The current market offer is USD63.00 per kilo EXW, up around 5.81% from last month and down 15.4% YoY.

Some analysts believe the reason for the rebound at this stage lies in the bottoming out of positions at the trade end. Mainstream manufacturers are strongly willing to raise the prices due to cost support.

The current market reference price is USD59.60/KG EXW, 4.56% up on the previous month and down 29.8% YoY. It’s still at a price stage suitable for purchase. Domestic and overseas market enquiries have increased, and the pressure on mainstream factories for order delivery has increased, leading to a continued upward trend in transaction prices.

Since late April, Tylosin and Tilmicosin prices have rebounded continuously, rising 5.3% and 7.0% year on year, respectively. In addition to reduced supply from manufacturers, the active building of positions in the trade channel has been the main factor supporting the recent price increases. We believe this is an appropriate time to buy, same as stated in our Newsletter dated April 30th.

For other veterinary APIs market information and solid inquiries, please feel free to contact us.

The overall domestic vitamin market was going stable and weak, with a solid wait-and-see mentality in the market. Influenced by the dual-control policy on energy consumption, tight supply of raw materials and rising costs, upstream factories kept releasing rumours of price increases, but unsatisfactory effect to mobilize the market prices. Due to the repeated outbreak of the Covid-19 in various cities, export volumes decreased significantly compared to the previous years, resulting in relatively sufficient stocks in the domestic market. Most of the varieties maintain weak prices. A few of them that have recently stopped quotation and prices have risen are worthy of more attention, such as D-calcium pantothenate, vitamin K3, choline chloride, etc.

NHU Company plans to carry out scheduled maintenance and renovation work on various product lines starting from mid-June and lasting ten weeks. It was disclosed on May 17 when NHU accepted a research team from funds, securities, insurance and other institutional units.This includes the vitamin A and E production lines.

The domestic price of vitamin A shows a continuous downward trend, and demand continues to be weak, of which the pandemic has a negative a negative impact to market consumption.

With a simple supply pattern and stable demand, vitamin E can be considered a dominant variety of vitamin feed supplements and an indicator product for the boom of the animal breeding industry. We should keep a close eye on the disturbance of relevant events to its market trend to ensure the stability and sustainability of the supply chain.

Most industry players believe it’s on a bullish trend. NHU Company said on May 17 to shut down its Shandong factory for maintenance for 8-9 weeks starting in mid-June.

After a period of active and rapid increases, D-Calphan is starting to go into consolidation and is focused on depleting stocks. Product offers vary slightly from brand to brand, and there is a case for price rise due to increasing costs. If demand picks up, then new prices will be reflected in the market.

Yifan Pharma implemented its annual maintenance plan in May and has resumed production. Guang'an Mojia Biotech has successfully finished trial production and entered commercial operation with the product being placed on the market.

A manufacturer raised the price straight to 650 RMB/kg (domestic market) on 24 May, and the export quotation was USD85/KG.

Since April this year, raw material prices rose, especially the price of imported chrome ore continued to grow, driving costs up significantly. On May 12, Zhenhua Minfeng and Brother Tech stopped quoting.

Zhenhua Minfeng vitamin K3 reached first place in output and market share globally after its restructuring from Zhenhua Corp and Minfeng Chemicals.

For further details of single and blend vitamins, please get in touch with us.

FEATURED PRODUCTS

Magicoh Pellet Binder provides a cost-efficient solution to meet your rigid binding requirements in all pelleted or extruded feed for shrimp, poultry,pig and cattle. Write to us or click here to go to our webpage for more information.

FLORDIS 100/200: Florfenicol 4% microencapsulated, 10% water-soluble, 20% water-soluble, 20% coated for the treatment of bacterial diseases of pigs, chickens and fish caused by sensitive bacteria, especially for respiratory system infections and intestinal.